KRAS and non-small cell lung carcinoma: This review highlights the clinical studies that have elucidated the potential prognostic and predictive implications of KRAS, STK11, and KRAS/STK11 co-mutations when treating metastatic NSCLC patients across various treatments (i.e., chemotherapy and immune checkpoint inhibitors).